somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Another disadvantage is that the input cell volume must be free of large cell clumps, which requires a pre-processing step (typically, by sonication). If cell clumps are not removed prior to processing, clogging of the valve occurs, and the unit must be cleaned thoroughly before the processing can continue. As a result, many protein purification labs find that the use of lysozyme and sonication is sufficient for routine bacterial protein expression. Other technologies, such as sonication and ball mills, are available for many of the same purposes, and have their own advantages and disadvantages. For example, sonication can generate high shear forces that break cellular DNA into small fragments. With a French press, the shear force can be carefully modulated by adjusting the piston pressure. The Press provides a single pass through the point of maximum shear force, limiting damage to delicate biological structures due to repeated shear, as occurs in other disruption methods.
A typical APCI source usually consists of three main parts: a sample inlet, a corona discharge needle, and an ion transfer region under intermediate pressure. In the case of the heated nebulizer inlet from an LC, as shown in the figure, the eluate flows at 0.2 to 2.0 mL/min into a pneumatic nebulizer which creates a mist of fine droplets. Droplets are vaporized by impact with the heated walls at 350–500 °C and carried by the nebulizer gas and an auxiliary gas into the ion molecule reaction region between the corona electrode and the exit counter-electrode. A constant current of 2–5 microamps is maintained from the corona needle. Sample ions are produced by ion-molecule reactions (as described below), and pass through a small orifice or tube into the ion transfer region leading to the mass spectrometer. Various geometries of ion source are possible, depending on application. When used with liquid chromatography, particularly at higher flow rates, the nebulizer is often positioned orthogonal to (or at a similarly steep angle to) the inlet of the mass spectrometer, so that solvent and neutral material does not contaminate the actual inlet of the mass spectrometer.
Machado, who won the 2025 Nobel Peace Prize, offered to share her award with Trump, calling the United States strike as "historic" and thanking him on behalf of the Venezuelan people. The Nobel Prize Committee rejected her request and clarified that the prize "cannot be revoked, shared or transferred".
== Case Study: Ocean Euxinia == Because green-pigmented green sulfur bacteria require higher light intensities than their brown-pigmented counterparts, the presence of chlorobactane in the rock record has been used as key evidence in interpretations for a very shallow euxinic layer in the ocean. The euxinic zone may have changed depth in the ocean at various points in Earth's history, such as with the advent of an oxygenated atmosphere around 2.45 billion years ago and the shallowing of the oxic zone within the last six kyr.
Sources: en.wikipedia.org
=== Middle East and North Africa (MENA) === In the Middle East and North Africa from 1990 to 2019, the prevalence of people with hip osteoarthritis increased three–fold over the three decades, a total of 1.28 million cases. It increased 2.88-fold, from 6.16 million cases to 17.75 million, between 1990 and 2019 for knee osteoarthritis. Hand osteoarthritis in MENA also increased 2.7-fold, from 1.6 million cases to 4.3 million from 1990 to 2019.
However, this can be possible: for example, inhibitors based on the compounds mycophenolic acid and tiazofurin inhibit IMP dehydrogenase at the NAD+ binding site. Because of the importance of this enzyme in purine metabolism, these compounds may be useful as anti-cancer, anti-viral, or immunosuppressive drugs. Other drugs are not enzyme inhibitors, but instead activate enzymes involved in NAD+ metabolism. Sirtuins are a particularly interesting target for such drugs, since activation of these NAD-dependent deacetylases extends lifespan in some animal models. Compounds such as resveratrol increase the activity of these enzymes, which may be important in their ability to delay aging in both vertebrate, and invertebrate model organisms. In one experiment, mice given NAD for one week had improved nuclear-mitochrondrial communication. Because of the differences in the metabolic pathways of NAD+ biosynthesis between organisms, such as between bacteria and humans, this area of metabolism is a promising area for the development of new antibiotics. For example, the enzyme nicotinamidase, which converts nicotinamide to nicotinic acid, is a target for drug design because this enzyme is absent in humans but present in yeast and bacteria. In bacteriology, NAD, sometimes referred to factor V, is used as a supplement to culture media for some fastidious bacteria. High-cost unlicensed infusions of NAD+ have been claimed in the UK to be "clinically proven" and "effective" treatment for alcoholism and drug abuse.
== Society and culture == Modafinil's use varies by region. In the US, it is approved for adult narcolepsy, shift work sleep disorder, and obstructive sleep apnea, but not for children. In the UK and the EU, since 2014, it is approved solely for narcolepsy, including in children (pediatric narcolepsy), with its use for other conditions restricted by the European Medicines Agency. Modafinil is not approved for use by children in multiple jurisdictions.
Sources: en.wikipedia.org
== Further reading == Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC).
On 9 October 2008, in an attempt to control the damage to Chinese dairy exports, officials at a World Trade Organization meeting insisted that contamination had been "accidental", directly contradicting the WHO observations. Chinese trade representatives criticised countries which have imposed blanket bans on Chinese food products. They urged member states to base import restrictions on scientific risk assessments, and to use official WTO notification mechanisms. On 11 October, Deputy Health minister Liu Qian stated that all the foreign companies' application for compensation for dairy products recall would be dealt with on a commercial basis, although government may use diplomatic channels if necessary, if problems were encountered.
=== Notable cases === As of April 2016, six hyperthymesia cases have been confirmed in peer-reviewed articles, the first being that of Jill Price (initially anonymised as "AJ") in 2006. More cases had been identified by 2012, but are yet to be published. Price's case was originally reported by researchers from the University of California, Irvine, Elizabeth Parker, Larry Cahill and James McGaugh, and is credited as being the first documented case of hyperthymesia. Price can apparently recall every day of her life from when she was 14 years old: "Starting on February 5, 1980, I remember everything. That was a Tuesday." In March 2009, Price was interviewed for an article in Wired magazine by Gary Marcus, a cognitive psychologist at New York University. Price's brain had been subject to a brain scan and the hippocampus and prefrontal cortex had been reportedly normal. Marcus claimed, however, that her brain resembled "those of people with obsessive-compulsive disorder" and suggested that her remarkable memory might be "the byproduct of obsession", claiming also that "the memory woman clings tightly to her past". Price strongly disputed this and McGaugh has also challenged the explanation. Price gave her first interview in over a year for the UK's Channel 4 documentary The Boy Who Can't Forget, and spoke of the challenges of living with the condition. K.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.